Stacey M Stein, MD

Assistant Professor of Medicine (Medical Oncology)

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center: Gastrointestinal Cancers Program

Subset Medical Oncology Faculty

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Internal Medicine AB of Internal Medicine (2007)

  • Medical Oncology AB of Internal Medicine (2010)

Clinical Trials

Conditions Study Title
Colon, Esophagus, Liver, Other Digestive Organ, Pancreas, Rectum, Small Intestine, Stomach A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Liver Randomized Phase II Trial of Chemoembolization and Sorafenib: Comparison Between Continuous and Sequential Treatment Regimens
Colon A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer
Colon TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Anus, Rectum A Phase II Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal
Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid A Phase Ia/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer
Esophagus, Liver, Other Digestive Organ, Pancreas, Stomach An Open-Label, Multicenter Phase Ib Study of The Safety and Tolerability of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab And/Or Other Treatments in Patients With Solid Tumors
Other Digestive Organ, Stomach A Phase Ib/II, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Colon, Rectum A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Stomach A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Esophagus A Phase I Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I An Open-Label, Multicenter, Phase I Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium
Pancreas A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Breast - Female, Breast - Male, Lung, Pancreas, Phase I Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Pancreas Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO)
Esophagus, Other Digestive Organ A Study of DKN-01 in Combination With Paclitaxel
Colon Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction
Colon S0820, Adenoma and Second Primary Prevention Trial (PACES)
Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach, Phase I A Study of MPDL3280A Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Edit this profile

Contact Info

Stacey M Stein, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 8

New Haven, CT 06511
View on map...
Mailing Address
PO Box 208032
New Haven, CT 06520-8032